What's breaking now, across thousands of outlets.
Germany's Merck KGaA agreed to buy UK drug developer Silence Therapeutics for $1.3 billion, building out its work in rare and specialty diseases using genetic medicines. Silence is developing the siRNA drug divesiran, which is ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Michael Lynch, from Men's Action Network (MAN) offered to meet the Derry City footballer James McClean.
A Russian attack on Kyiv on Oct. 19 damaged the Consultative and Diagnostic Center at Kyiv City Clinical Hospital No. 6 in the Solomianskyi district, forcing it to suspend operations, the Kyiv City…
KUALA LUMPUR – As scientists, economists, financiers, and policymakers gathered to discuss the impact of climate at the Global Tipping Points conference last week, the air quality in the Malaysian…
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.
Machine learning analysis reveals that different sensory experiences in autistic children correspond to unique patterns of brain connectivity.
The exercise, according to health officials, will cover girls aged between 9 to 14 years who have previously not received the vaccine.
